@article{5d4274a0fdb8461cae765df3b7a24609,
title = "The diagnosis and management of allergic reactions in patients sensitized to non-specific Lipid Transfer Proteins",
abstract = "Sensitization to one or more non-specific lipid transfer proteins (nsLTPs), initially thought to exist mainly in southern Europe, is becoming accepted as a cause of allergic reactions to plant foods across Europe and beyond. The peach nsLTP allergen Pru p 3 is a dominant sensitizing allergen and peaches a common food trigger, although multiple foods can be involved. A frequent feature of reactions is the requirement for a cofactor (exercise, alcohol, non-steroidal anti-inflammatory drugs, Cannabis sativa) to be present for a food to elicit a reaction. The variability in the food and cofactor triggers makes it essential to include an allergy-focused diet and clinical history in the diagnostic workup. Testing on suspected food triggers should also establish whether sensitization to nsLTP is present, using purified or recombinant nsLTP allergens such as Pru p 3. The avoidance of known trigger foods and advice on cofactors is currently the main management for this condition. Studies on immunotherapy are promising, but it is unknown whether such treatments will be useful in populations where Pru p 3 is not the primary sensitizing allergen. Future research should focus on the mechanisms of cofactors, improving diagnostic accuracy and establishing the efficacy of immunotherapy.",
author = "{European Academy of Allergy, Clinical Immunology (EAACI) Task Force: Non-specific Lipid Transfer Protein Allergy Across Europe} and Skypala, {I J} and J Bartra and Ebo, {D G} and Faber, {M A} and M Fern{\'a}ndez-Rivas and F Gomez and O Luengo and Till, {S J} and R Asero and D Barber and L Cecchi and {Diaz Perales}, A and K Hoffmann-Sommergruber and Pastorello, {E A} and I Swoboda and Konstantinopoulos, {A P} and {van Ree}, R and E Scala",
note = "Funding Information: Dr. Fernandez‐Rivas reports grants from Spanish Government, grants and personal fees from Aimmune Therapeutics, grants and personal fees from Diater, personal fees from DBV, personal fees from Novartis, personal fees from SPRIM, personal fees from GSK, personal fees from HAL Allergy and personal fees from Thermo Fisher Scientific, outside the submitted work. Dr. Barber reports grants from ALK, personal fees from ALK and AIMMUNE and grants from Allero Therapeutics, outside the submitted work. Dr. Hoffmann‐Sommergruber reports grants from Government of Lower Austria {\textquoteleft}Danube Allergy Research Cluster{\textquoteright}, and non‐financial support from Task Force supported by EAACI, during the conduct of the study. Dr. van Ree reports personal fees from HAL Allergy BV, personal fees from Citeq BV, personal fees from Angany Inc and personal fees from Thermo Fisher Scientific, outside the submitted work. Dr. Skypala, Dr. Bartra, Dr. EBO, Dr. Faber, Dr. GOMEZ, Dr. Till, Dr. Luengo, Dr. Asero, Dr. Cecchi, Dr. D{\'i}az Perales, Dr. Pastorello, Dr. Swoboda, Dr. Konstantinopoulos and Dr. SCALA have nothing to disclose. Publisher Copyright: {\textcopyright} 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = aug,
doi = "10.1111/all.14797",
language = "English",
volume = "76",
pages = "2433--2446",
journal = "Allergy",
issn = "0105-4538",
publisher = "John Wiley and sons",
number = "8",
}